We are live on ! Find out more
FBRX icon

Forte Biosciences
FBRX

61 hedge funds and large institutions have $51.5M invested in Forte Biosciences in 2018 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 12 increasing their positions, 18 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 3

41% more call options, than puts

Call options by funds: $768K | Put options by funds: $545K

5% more funds holding

Funds holding: 58 → 61 (+3)

0.01% less ownership

Funds ownership: 0.08% → 0.07% (-0.01%)

31% less capital invested

Capital invested by funds: $74.7M → $51.5M (-$23.2M)

33% less repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 18

Holders
61
Holders Change
+3
Holders Change %
+5.17%
% of All Funds
1.4%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
12
Reduced
18
Closed
3
Calls
$768K
Puts
$545K
Net Calls
+$223K
Net Calls Change
-$53K

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$608K
2
6CM
683 Capital Management
New York
+$487K
3
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
+$483K
4
State Street
State Street
Massachusetts
+$282K
5
JMPWA
JP Morgan Private Wealth Advisors
California
+$176K

Top Sellers

Rank Fund Capital Flow
1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$4.62M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$2.69M
3
JP Morgan Chase
JP Morgan Chase
New York
-$1.88M
4
BI
BVF Inc
California
-$326K
5
BP
BBR Partners
New York
-$267K
Name Holding Trade Value Shares
Change 		Change in
Stake
BlackRock
1
BlackRock
New York
$10.5M +$608K +166 +6%
Vanguard Group
2
Vanguard Group
Pennsylvania
$6.41M +$139K +38 +2%
Fidelity Investments
3
Fidelity Investments
Massachusetts
$4.78M -$2.69M -735 -35%
BI
4
BVF Inc
California
$4.4M -$326K -89 -7%
JP Morgan Chase
5
JP Morgan Chase
New York
$3.52M -$1.88M -513 -34%
T. Rowe Price Associates
6
T. Rowe Price Associates
Maryland
$2.97M -$4.62M -1,261 -60%
State Street
7
State Street
Massachusetts
$1.98M +$282K +77 +16%
Northern Trust
8
Northern Trust
Illinois
$1.7M – – –
FCMI
9
Foresite Capital Management III
California
$1.39M – – –
CI
10
CPMG Inc
Texas
$1.35M – – –
Geode Capital Management
11
Geode Capital Management
Massachusetts
$950K +$98.9K +27 +11%
AG
12
Artal Group
Luxembourg
$934K – – –
BCM
13
Bridgeway Capital Management
Texas
$934K – – –
Russell Investments Group
14
Russell Investments Group
United Kingdom
$757K – – –
CBT
15
Capital Bank & Trust
California
$467K – – –
6CM
16
683 Capital Management
New York
$467K +$487K +133 New
Jacobs Levy Equity Management
17
Jacobs Levy Equity Management
New Jersey
$463K +$483K +132 New
LSAG
18
Lake Street Advisors Group
New Hampshire
$458K – – –
Morgan Stanley
19
Morgan Stanley
New York
$447K -$11K -3 -2%
Bank of New York Mellon
20
Bank of New York Mellon
New York
$438K -$62.3K -17 -12%
Victory Capital Management
21
Victory Capital Management
Texas
$438K – – –
GIM
22
Granahan Investment Management
Massachusetts
$396K +$54.9K +15 +15%
BF
23
Blankinship & Foster
California
$376K – – –
Deutsche Bank
24
Deutsche Bank
Germany
$369K +$135K +37 +54%
CG
25
Colony Group
Massachusetts
$347K – – –
1
2 3

FBRX Hedge Fund Activity: Q2 2018 in Review

61 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Forte Biosciences (FBRX) for Q2 2018, worth a combined $51.5M — down 31% from $74.7M a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new FBRX positions and 3 closed out — a net gain of 3 holders — while 12 added to existing stakes and 18 trimmed.

The largest buyer was BlackRock, adding an estimated $608K. The largest seller was T. Rowe Price Associates, cutting an estimated $4.62M.

  • 61 institutional investors held Forte Biosciences (FBRX) as of Q2 2018, up from 58 in Q1 2018.
  • Funds reported $51.5M of Forte Biosciences stock for Q2 2018, down 31% quarter-over-quarter.
  • 6 funds opened new Forte Biosciences positions in Q2 2018 and 3 closed out, a net change of +3 holders.
  • The largest Forte Biosciences buyer in Q2 2018 was BlackRock, an estimated $608K added.
  • The largest Forte Biosciences seller in Q2 2018 was T. Rowe Price Associates, an estimated $4.62M sold.

Based on aggregated 13F filings for Q2 2018.